)
Bafna Pharmaceuticals today said it has launched pain management and anti-infective products in the domestic market as it looks to expand presence in these segments.
"The company is expanding its base into pain management and anti-infectives by launching Afenac-P tablets, Afnec Th tablets, Nocaf syrup, Izabof suspension and Izabof 250 and 500 mg tablets," Bafna Pharmaceuticals said in a filing to BSE.
The company already has a presence in the domestic market in the women wellness and childcare segments with the launch of Raricap group of products, it added.
Bafna Pharma scrip closed at Rs 30.20, down 0.17%, on the BSE.
